ELA: Elan Corporation PLC: Elan Announces the Appointment of

a New Board Director 
UK Regulatory Announcement
DUBLIN, Ireland 
Elan Corporation, plc today announced the appointment of Mr. William
R. Rohn to the company's Board of Directors. 
Elan's chairman, Kyran McLaughlin, said, "The Board is extremely pleased to
announce the appointment of Bill. His extensive experience in the pharmaceutical
and biotech industries, together with his personal qualities, will make him an
excellent addition to the Board and we all look forward to working with him". 
Kelly Martin, Elan's president and chief executive officer, added: "I look
forward to working with Bill and benefiting from the experience he brings with
him". 
Mr. Rohn (62) is an experienced biotech and pharmaceutical industry executive.
He is currently Vice Chairman of Raven Biotechnologies, Inc., and a Director of
Metabasis Therapeutics, Inc., Cerus Corp and Pharmacyclics, Inc. Previously he
was Chief Operating Officer of Biogen Idec until January 2005 and prior thereto
President and Chief Operating Officer of Idec Pharmaceutical Corporation from
1993. 
About Elan 
Elan Corporation, plc is a neuroscience-based biotechnology company committed to
making a difference in the lives of patients and their families by dedicating
itself to bringing innovations in science to fill significant unmet medical
needs that continue to exist around the world. Elan shares trade on the New
York, London and Dublin Stock Exchanges. For additional information about the
company, please visit http://www.elan.com. 
CONTACT: Elan Corporation, plc 
Investor Relations: 
Emer Reynolds, 353-1-709-4000 
or 
Chris Burns, 800-252-3526 
or 
Media Relations: 
Davia Temin, 212-407-5740 
or 
Elizabeth Headon, 353-1-498-0300 
CONTACT:
Elan Corporation PLC
 
 
Press spacebar to pause and continue. Press esc to stop.